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Abstract
Introduction The purpose of this analysis was to determine the
potential efficacy of recombinant human tissue factor pathway
inhibitor (tifacogin) in a subpopulation of patients with
community-acquired pneumonia (CAP) from a phase III study of
severe sepsis.
Methods A retrospective review of patients with suspected
pneumonia was conducted by an independent clinical
evaluation committee (CEC) blinded to treatment assignment.
The CEC reanalyzed data from patients enrolled in an
international multicenter clinical trial of sepsis who had a
diagnosis of pneumonia as the probable source of sepsis. The
primary efficacy measure was all-cause 28-day mortality.
Results Of 847 patients identified on case report forms with a
clinical diagnosis of pneumonia, 780 (92%) were confirmed by
the CEC to have pneumonia. Of confirmed pneumonia cases,
496 (63.6%) met the definition for CAP. In the CEC CAP
population, the mortality rates of the tifacogin and placebo
groups were 70/251 (27.9%) and 80/245 (32.7%),
respectively. The strongest signals were seen in patients with
CAP not receiving concomitant heparin, having
microbiologically confirmed infection, or having the combination
of documented infection and no heparin. The reduction in
mortality in this narrowly defined subgroup when treated with
tifacogin compared with placebo was statistically significant
(17/58 [29.3%] with tifacogin and 28/54 [51.9%] with placebo;
unadjusted P value of less than 0.02).
Conclusions Tifacogin administration did not significantly
reduce mortality in any severe CAP patient. Exploratory analyses
showed an improved survival in patients who did not receive
concomitant heparin with microbiologically confirmed infections.
These data support the rationale of an ongoing phase III study
exploring the potential benefit of tifacogin in severe CAP.
Trial Registration ClinicalTrials.gov identifier NCT00084071.
Introduction
Sepsis is a systemic response to infection associated with sig-
nificant mortality and substantial direct patient care costs [1].
Community-acquired pneumonia (CAP) is the most common
cause of sepsis [2-5]. CAP mortality rates are significant and
have not changed significantly over several decades despite
the availability of improved broad-spectrum antibiotics [6].
While successful outcome from severe CAP requires
APACHE II: Acute Physiology and Chronic Health Evaluation II; aPC: activated protein C; CAP: community-acquired pneumonia; CEC: clinical eval-
uation committee; CRF: case report form; HAP: hospital-acquired pneumonia; LPS: lipopolysaccharide; OPTIMIST: Optimized Phase III Tifacogin in 
Multicenter International Sepsis Trial; PCT: procalcitonin; TF: tissue factor; TFPI: tissue factor pathway inhibitor.Critical Care    Vol 13 No 2    Laterre et al.
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adequate treatment of the infection, antimicrobial agents alone
have only limited capacity to reduce the mortality rate associ-
ated with severe CAP and adjunctive measures are required to
treat organ dysfunction such as respiratory failure [6].
Likely contributors to organ dysfunction and death are intra-
vascular and intrapulmonary generation of thrombin and depo-
sition of fibrin due to break down in hemostatic regulation.
Increased cell surface expression of tissue factor (TF) in
severe CAP induces thrombin generation and fibrin formation
[7,8]. TF expression in the lungs of pneumonia patients leads
to a proinflammatory and procoagulant environment as well as
to decreased fibrinolysis [9].
TF pathway inhibitor (TFPI) regulates coagulation initiated by
TF. Expression of TF and TFPI is imbalanced in acute lung
injury [10]. Administration of recombinant TFPI or factor VIIa
antagonists reduces lung injury and systemic cytokine
responses in infection models [11-14]. Therefore, TF inhibition
may have beneficial effects in disease states such as acute
lung injury or pneumonia in which coagulation and inflamma-
tion play prominent roles [9].
Safety and efficacy of tifacogin, a recombinant form of human
TFPI, were assessed in a phase III study (TFP007 OPTIMIST
[Optimized Phase III Tifacogin in Multicenter International Sep-
sis Trial]) in patients with severe sepsis [15]. Although efficacy
of the primary endpoint of 28-day all-cause mortality was not
shown, treatment benefit in a subset of patients with pneumo-
nia with microbiological documentation and not receiving
heparin within 24 hours prior to and/or during study drug infu-
sion was observed in post hoc analysis. However, these anal-
y s e s  w e r e  b a s e d  o n  c a s e  r e p o r t  f o r m s  ( C R F s )  i n  w h i c h
investigators were allowed to list multiple sites of infection and
any positive cultures. Not all positive cultures grew pathogens,
and the organisms grown were not necessarily consistent with
the suspected infection site.
Concern regarding the accuracy of subgroup classification in
TFP007 prompted the creation of a clinical evaluation commit-
tee (CEC) to validate the CRF-based analyses. CECs have
previously been engaged to evaluate negative trials of adjuvant
agents in critical illness in order to determine a target popula-
tion for further study [16,17]. The CEC was specifically
charged with determining (a) the validity of the pneumonia
diagnosis, (b) whether the pneumonia was CAP, hospital-
acquired pneumonia (HAP), or other diagnoses, and (c) the
level of evidence of a microbiological etiology of CAP.
Materials and methods
A detailed description of the study was previously published
[15]. The OPTIMIST study was approved by the ethics com-
mittee of each individual participating center, and written con-
sent was obtained from each patient or next of kin. The CEC
retrospective study was approved by the ethics committee of
St Luc University Hospital (Brussels, Belgium). Initial analyses
of the TFP007 patient subgroup with pneumonia used a pro-
grammatic definition of CAP that allowed a maximum of 2 days
of hospitalization prior to the start of study drug for the pneu-
monia to be classified as CAP. Patients hospitalized longer
than 2 days were classified as having HAP.
The CEC consisted of critical care, pulmonary disease, and
infectious disease specialists who remained blinded to treat-
ment throughout the evaluation. A charter incorporating a pre-
determined set of clinical and microbiological classification
rules was used to ensure uniformity of this retrospective
assessment [18]. Criteria to be classified as CAP included all
five of the following: (a) the clinical and radiographic evidence
was consistent with pneumonia, (b) microbiology (when pro-
vided) was consistent with a CAP pathogen, (c) the primary
reason for hospital admission was pneumonia, (d) there was
no evidence of aspiration or major immunocompromised state,
and (e) the patient was not a known nursing home resident or
transfer from another institution. Chest x-ray protocol provided
by a radiologist at each investigator site was used to define
evidence of CAP. In the CEC analysis, the CAP time window
was expanded to 4 days between hospital admission and start
of study drug infusion for cases with signs and symptoms of
CAP on admission. This interval was chosen based on the time
windows used for patient enrollment [19] and to include CAP
patients who deteriorated after admission [20,21].
TFP007 investigators classified 847 patients as having CAP
on the CRFs. Cases in which pneumonia was not listed by the
investigator as a potential site of infection were not reviewed.
The CEC reviewed all available information on CRFs from the
locked TFP007 database for those subjects. Each case was
independently reviewed by one member, and then the CEC
met to reach a consensus on all problematic cases. No adju-
dication of any outcome data was performed.
The CEC assessment forms were tabulated, and the tifacogin
arm was compared with placebo for all CEC-confirmed CAP
cases. Additional analyses were carried out for microbiological
evidence (based on culture only), heparin use, serious bleed-
ing events and contributing causes, and the Acute Physiology
and Chronic Health Evaluation II (APACHE II) score quartiles
[4,22]. The results of the CEC evaluation were compared with
those of the original programmatic classification.
Elevated procalcitonin (PCT) (>0.5 ng/mL) levels are associ-
ated with a bacterial etiology in patients presenting with sus-
pected pulmonary infection [23]. PCT levels were measured in
plasma specimens prospectively collected (Brahms AG, Hen-
nigsdorf, Germany). The CEC classification was performed
without knowledge of PCT values. PCT levels were evaluated
in the CEC-designated CAP population. Chi-square tests
were used to compare treatment groups for dichotomous var-
iables. All P values are unadjusted for multiple testing. LogisticAvailable online http://ccforum.com/content/13/2/R36
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regression models were also used to adjust for baseline
APACHE II score, PCT level, shock, and use of ventilator
support.
Results
Confirmation of pneumonia and community-acquired 
pneumonia diagnosis
In its review of 847 patients identified on CRFs with a diagno-
sis of pneumonia, the CEC concurred that pneumonia was the
cause of sepsis in 780 cases (92%). One patient could not be
evaluated. Of the 780 confirmed pneumonia cases, 496 were
classified by the CEC as CAP (251 in the tifacogin group and
245 in the placebo group) and 259 were classified as HAP
(132 in the tifacogin group and 127 in the placebo group).
Because of a major immunocompromised state, aspiration, or
radiation pneumonitis, 25 patients did not meet the standard
definition of CAP and therefore were excluded. The CRF-
defined pneumonia subgroup identified pneumonia patients
misclassified as having CAP when they actually had HAP and
vice versa.
Demographics of the 496 CEC CAP patients are presented in
Table 1. Sixty-eight percent received heparin and 65% had a
microbiologically confirmed infection. Baseline characteristics
in the placebo and tifacogin groups were similar. For both doc-
umented CAP and no-heparin-use subgroups, baseline
APACHE II scores and presence of shock did not differ
between TFPI and placebo.
The spectrum of etiologic microorganisms is presented in
Table 2. Streptococcus pneumoniae was the most common
pathogenic organism. Twelve cases had only sputum Gram
stain evidence of pneumonia. Baseline PCT levels above 2 ng/
mL were present in the majority (78%) of CEC CAP patients.
Table 1
Baseline demographics for clinical evaluation committee community-acquired pneumonia patients
Tifacogin
n = 251
Placebo
n = 245
Selected
P value
Age in years, mean ± standard deviation 60.5 ± 15.8 60.2 ± 15.1
Gender, number (percentage)
Female 91 (36) 100 (41)
Male 160 (64) 145 (59)
Ethnicity, number (percentage)
Caucasian 207 (82) 199 (81)
Black 26 (10) 20 (8)
Hispanic 9 (4) 12 (5)
Asian 5 (2) 7 (3)
Other 4 (2) 7 (3)
Baseline APACHE II score
Mean ± standard deviation 25.6 ± 7.0 25.2 ± 6.7
Baseline interleukin-6 434.6 478.9
Geometric mean (95% CI) (329.2, 573.6) (355.1, 645.9)
Baseline procalcitonin
Geometric mean (95% CI) 8.89 (7.15, 11.05) 8.09 (6.35, 10.31)
<2 ng/mL, number (percentage) 50 (20) 60 (25)
Shock, number (percentage) 163 (65) 176 (72) 0.10
Ventilatory support, number (percentage) 193 (77) 200 (82) 0.19
Number of organ dysfunctions, number (percentage)
Two or less 87 (35) 72 (29) 0.21
Three or more 164 (65) 173 (71)
Heparin use, number (percentage) 172 (69) 167 (68)
Organism identified, number (percentage) 170 (68) 154 (63)
APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval.Critical Care    Vol 13 No 2    Laterre et al.
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Only 60/245 (25%) of placebo and 50/251 (20%) tifacogin-
treated patients had PCT levels of less than 2 ng/mL.
Effect of tifacogin in clinical evaluation committee 
community-acquired pneumonia cohort
Kaplan-Meier plots of 28-day cumulative survival data for all
CEC CAP patients (Figure 1) and for CEC CAP subjects who
did not receive heparin and who also had microbiological evi-
dence of an infectious etiology for their pneumonia (Figure 2)
are shown. The CEC CAP patients treated with tifacogin had
lower 28-day all-cause mortality compared with the placebo
group (27.9% versus 32.7%; P = 0.25, Pearson chi-square
test; P = 0.22, logistic regression model). The largest differ-
ence in 28-day mortality (Table 3 and Figure 2) occurred in the
subgroup of patients with microbiological evidence of infec-
tion in the no-heparin CAP cohort (29.3%, tifacogin; 51.9%,
placebo; P = 0.02, Pearson chi-square test; P = 0.02, logistic
regression model).
Effect of pathogen class and causative microorganism 
on mortality
The observed mortality of the tifacogin-treated group was
lower than that of the placebo group for all pathogen classes
(Gram-positive, Gram-negative, mixed, and other) (Figure 3)
and when analyzed by individual pathogen, except unusual
respiratory pathogens and respiratory viruses (Table 2). For S.
pneumoniae, the observed 28-day mortality in tifacogin-
treated subjects was 20.3% versus 27.1% in the placebo arm.
Table 2
Clinical evaluation committee classification of causative microorganisms in community-acquired pneumonia patients
Tifacogin
n = 251
Placebo
N = 245
Organism identified Number (percentage) Mortality, number (percentage) Number (percentage) Mortality, number (percentage)
Streptococcus pneumoniae 69 (27.5) 14 (20.3) 70 (28.6) 19 (27.1)
Staphylococcus aureus 33 (13.1) 14 (42.4) 19 (7.8) 12 (63.2)
Haemophilus influenzae 26 (10.4) 5 (19.2) 10 (4.1) 5 (50)
Other respiratory organisms 24 (9.6) 9 (37.5) 23 (9.4) 6 (26.1)
Enteric Gram-negative 20 (8.0) 6 (30) 16 (6.5) 9 (56.3)
Gram stain only 9 (3.6) 3 (33.3) 9 (3.7) 4 (44.4)
Legionella species 6 (2.4) 1 (16.7) 10 (4.1) 2 (20)
Pseudomonas aeruginosa 6 (2.4) 1 (16.7) 12 (4.9) 5 (41.7)
Respiratory viruses 2 (0.8) 1 (50) 0 0
Chlamydophila pneumoniae 00 2  ( 0 . 8 ) 0
No organism identified 81 (32.3) 91 (37.1)
Figure 1
Kaplan-Meier survival analysis for all clinical evaluation committee  (CEC) community-acquired pneumonia (CAP) patients Kaplan-Meier survival analysis for all clinical evaluation committee 
(CEC) community-acquired pneumonia (CAP) patients. P value = 0.25.
Figure 2
Kaplan-Meier survival analysis for clinical evaluation committee commu- nity-acquired pneumonia patients in the non-heparin cohort with micro- organism identified Kaplan-Meier survival analysis for clinical evaluation committee commu-
nity-acquired pneumonia patients in the non-heparin cohort with micro-
organism identified. P value = 0.02.Available online http://ccforum.com/content/13/2/R36
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When analyzed by PCT levels of less than 2 ng/mL and of
greater than or equal to 2 ng/mL, the observed mortality in the
tifacogin-treated cohort was improved in subjects with higher
PCT levels (Table 3).
Tifacogin treatment effect and APACHE II score
Based on PROWESS (Recombinant Human Activated Pro-
tein C Worldwide Evaluation in Severe Sepsis) [4,22], CEC
CAP patients were segregated into quartiles of APACHE II
scores of less than 20 (n = 91), 20 to 24 (n = 149), 25 to 29
(n = 127), and greater than 29 (n = 128) (Figure 4). In both
tifacogin and placebo groups, mortality increased with higher
APACHE II scores. Mortality for patients receiving tifacogin
was lower than mortality in the placebo group in all four
APACHE II score quartiles.
Safety
The overall incidence of all adverse events was similar in the
tifacogin group (93%) and the placebo group (91%). Serious
adverse event rates, likewise, were similar (41% versus 52%,
respectively). Since tifacogin is an anticoagulant, the inci-
dence of events involving bleeding was scrutinized. Tifacogin-
treated CAP patients had higher rates of bleeding events
(23% versus 18%) and serious bleeding events (6% versus
2%) compared with placebo CAP patients. The most common
sites of bleeding were the gastrointestinal and respiratory
tracts in the tifacogin group and the gastrointestinal tract and
skin (ecchymoses) in the placebo group. Higher rates of
bleeding events occurred in subgroups receiving concomitant
heparin (Tables 4 and 5) than in those not treated with heparin.
Discussion
Retrospective subgroup analyses may identify potential target
populations for future trials. The OPTIMIST trial [15] showed
no improvement in mortality with tifacogin compared with pla-
cebo. Overall, the 28-day survival in patients with CAP treated
with tifacogin was higher compared with placebo but the dif-
ference did not reach statistical significance. However, sub-
group analysis of this study suggested that patients not
receiving heparin and/or with microbiological evidence of
Table 3
Mortality (28-day) in tifacogin and placebo groups for all patients and by microbiology status and heparin use
Tifacogin Placebo P value
All Mortality All Mortality
Number Number Percentage Number Number Percentage
All community-acquired pneumonia patients 251 70 27.9 245 80 32.7 0.25
Microbiology status
Organism identified 170 46 27.1 154 55 35.7 0.09
Organism not identified 81 24 29.6 91 25 27.5 0.75
Procalcitonin level
<2 50 15 30.0 60 18 30.0 1.00
 2 200 55 27.5 183 62 33.9 0.18
Heparin use
N o  H e p a r i n 7 9 2 32 9 . 17 8 3 34 2 . 3 0 . 0 8
Heparin 172 47 27.3 167 47 28.1 0.87
Microbiology status and heparin use
No heparin/Organism identified 58 17 29.3 54 28 51.9 0.02
No heparin/Organism not identified 21 6 28.6 24 5 20.8 0.54
Shock
Yes 163 50 30.7 176 64 36.4 0.27
No 88 20 22.7 69 16 23.2 0.95
Ventilatory support
Yes 193 60 31.1 200 75 37.5 0.18
No 58 10 17.2 45 5 11.1 0.38
Number of organ dysfunctions
Two or less 87 17 19.5 72 13 18.1 0.81
Three or more 164 53 32.3 173 67 38.7 0.22Critical Care    Vol 13 No 2    Laterre et al.
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pneumonia appeared to benefit from tifacogin. Using blinded
and stringent evaluations, the CEC strengthened the database
used for reanalysis, demonstrating an important role for CECs
in retrospective review. The CEC analysis corroborated the ini-
tial analysis by showing a reduction in mortality in the tifacogin-
treated CAP subgroup, not receiving heparin, with
microbiologically confirmed infection, or when these two con-
ditions were present.
Benefit of an agent affecting the coagulation pathway in a pop-
ulation with pneumonia versus other sources of infection has
biological plausibility. In animal models of acute bronchopneu-
monia, activation of coagulation can be readily demonstrated
[24,25]. Bronchoalveolar lavage specimens from patients with
acute lung injury also indicate activation of coagulation [26].
Recombinant human activated protein C (aPC), an anticoagu-
lant approved for the treatment of severe sepsis, had its great-
est benefit in the population with severe CAP in a similar CEC
analysis [19].
PCT has been shown to be consistently elevated in bacterial
infections [23,27]. The beneficial effect of tifacogin in patients
with levels above 2 ng/mL reinforces the need for the phase III
confirmatory study to emphasize documented bacterial CAP.
Both microbiological data and the PCT levels suggest that
tifacogin may have a disproportionate beneficial effect in
microbiologically confirmed cases of CAP.
The finding of a beneficial effect of tifacogin in patients with
microbiologically confirmed infection has several potential
explanations. Opal and colleagues [28] demonstrated that
patients with severe sepsis with a microbiologically confirmed
infection had greater perturbations of their coagulation and
inflammatory parameters compared with patients with culture-
negative severe sepsis. The ability to recover an organism may
indicate a patient with greater activation of the coagulation
system, a more pronounced proinflammatory stimulus, or both.
Recombinant human TFPI binds to lipopolysaccharides
(LPSs) and blocks LPS interaction with LPS-binding protein
[29]. Endotoxemia may occur in both Gram-positive and
Gram-negative cases of pneumonia [30]. This finding raises
the possibility that tifacogin exerts a beneficial effect via
immune signaling activities. Finally, tifacogin could potentially
play a role in aiding bacterial clearance, which would explain
this differential benefit in culture-positive cases [31]. There-
fore, three potential mechanisms of action whereby tifacogin
may benefit patients with severe CAP are (a) coagulation reg-
ulation, (b) immune modulation, and (c) bacterial clearance.
The clinical relevance of this hypothesis remains unknown.
In contrast to results in the no-heparin cohort, no benefit of
tifacogin was found in CAP patients who received heparin.
This result can possibly be explained by potential interactions
of tifacogin and heparin. TFPI is most active when expressed
on the surface of the cell [32]. Heparin initiates intracellular
signaling that results in the transfer of endothelial cell surface-
bound TFPI to intracellular storage vesicles, decreasing activ-
ity. Heparin could also result in TFPI release into the blood-
stream, where it is eventually degraded and is no longer active.
In addition, the heparin-binding site on TFPI overlaps the LPS-
binding site in the third Kunitz region and carboxyl terminus
and competes with TFPI LPS binding [30]. Such an effect
could interfere with tifacogin biological activity, suggesting the
possibility of a true drug-drug interaction to explain the neutral-
ization of beneficial effect of tifacogin by heparin.
An apparent mortality benefit of heparin use in the placebo
group has been noted in several sepsis trials using anticoagu-
lant therapies. However, patients were not randomly assigned
to heparin or no-heparin treatment; they were randomly
assigned to the study drug only. Investigators used heparin at
their discretion and it is reasonable to assume that heparin use
would be selected for patients who were less critically ill and
less likely to have major coagulopathies. Patients who died
early in the course of their illness after random assignment did
Figure 3
Mortality by bacterial Gram stain morphology in clinical evaluation com- mittee community-acquired pneumonia patients Mortality by bacterial Gram stain morphology in clinical evaluation com-
mittee community-acquired pneumonia patients.
Figure 4
Mortality by Acute Physiology and Chronic Health Evaluation II  (APACHE II) score quartiles in clinical evaluation committee commu- nity-acquired pneumonia patients treated with tifacogin or placebo Mortality by Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score quartiles in clinical evaluation committee commu-
nity-acquired pneumonia patients treated with tifacogin or placebo. The 
quartiles were determined by PROWESS (Recombinant Human Acti-
vated Protein C Worldwide Evaluation in Severe Sepsis) trial results.Available online http://ccforum.com/content/13/2/R36
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not have the opportunity to receive heparin. While the benefit
of heparin is likely due to the unequal allocation and selection
bias [17], a beneficial effect of heparin alone cannot be
excluded. A randomized controlled trial of unfractionated
heparin for sepsis is currently under way (ClinicalTrials.gov
identifier NCT00100308). However, because of both poten-
tial confounding and the possible drug-drug interaction, the
phase III confirmation study will require exclusion of heparin
therapy during the time of active treatment. TFPI has not been
demonstrated to be efficacious for the prevention of deep
venous thrombosis in critically ill patients. Mechanical com-
pression devices, an acceptable alternative for critically ill
patients at increased risk of bleeding (American College of
Chest Physicians guidelines), would therefore be required for
both treated and placebo groups.
An additional finding in the CEC CAP subgroup is the appar-
ent absence of a disease severity interaction. Though not
reaching statistical significance, the mortality rates in the
tifacogin-treated arm were consistently lower than those in the
placebo arm in all four APACHE II score quartiles. This finding
is unlike results of other clinical trials involving anti-inflamma-
tory compounds and aPC [33].
Incidence rates of adverse events and events associated with
bleeding in CAP patients receiving tifacogin were similar to
those in the original TFP007 patient population [15]. Bleeding
risk increased in CAP patients receiving both heparin and
tifacogin, further emphasizing that tifacogin should not be
coadministrated with heparin. Most patients who experienced
serious bleeding events had pre-existing conditions that put
them at increased risk for hemorrhagic complications.
CEC analyses of large phase III databases have recognized
limitations. These evaluations are retrospective in nature and
Table 4
Incidence of serious bleeding adverse events in patients with and without concomitant heparin use
MedDRA system organ class Number (percentage) of subjectsa
Heparin cohort Non-heparin cohort
Tifacogin Placebo 0.025 TFPI Placebo
(n = 172) (n = 167) (n = 79) (n = 78)
Any serious adverse event 11 (6%) 4 (2%) 3 (4%) 2 (3%)
Gastrointestinal disorders 1 (1%) 2 (1%) 2 (3%) 2 (3%)
General disorders and administration site condition 1 (1%) 1 (1%) 0 0
Injury and poisoning 0 1 (1%) 0 0
Nervous system disorders 3 (2%) 0 0 0
Respiratory, thoracic, and mediastinal disorders 1 (1%) 0 0 0
Surgical and medical procedures 2 (1%) 0 0 0
Vascular disorders 3 (2%) 0 1 (1%) 0
aNumber and percentage of subjects with one or more events that map to each MedDRA system organ class. Hence, MedDRA system organ 
class counts may not equate with overall counts. MedDRA, Medical Dictionary for Regulatory Activities; TFPI, tissue factor pathway inhibitor.
Table 5
Incidence of central nervous system bleeding events in placebo- and tifacogin-treated patients with and without concomitant 
heparin use
MedDRA system organ class Number (percentage) of subjectsa
Heparin cohort Non-heparin cohort
Tifacogin Placebo 0.025 TFPI Placebo
(n = 172) (n = 167) (n = 79) (n = 78)
Any serious adverse event 5 (3%) 0 1 (1%) 0
Nervous system disorders 3 (2%) 0 0 0
Vascular disorders 2 (1%) 0 1 (1%) 0
aNumber and percentage of subjects with one or more events that map to each MedDRA system organ class. Hence, MedDRA system organ 
class counts may not equate with overall counts. MedDRA, Medical Dictionary for Regulatory Activities; TFPI, tissue factor pathway inhibitor.Critical Care    Vol 13 No 2    Laterre et al.
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are based on progressively smaller subgroup sizes, leading to
an increasing potential for error. Retrospective analyses of
CAP patients' data include an additional hazard: they lack
assessment of adequacy of antimicrobial therapy. As is typical
of retrospective subgroup analyses, this analysis of a small
subgroup of severe CAP patients is solely hypothesis-gener-
ating. A subsequent study to test the hypothesis developed by
subgroup analysis is more likely to succeed if underlying bio-
logical principles support the use of the molecule in that
defined population. While the statistical tests are not cor-
rected for the number of subgroups examined, these data and
supportive evidence from the literature strengthen the hypoth-
esis that the best target for tifacogin is a population with
severe CAP in the absence of concomitant heparin use.
Conclusions
From this retrospective review of patients with severe CAP
evaluating the role of tifacogin administration, exploratory anal-
yses showed an improved survival in patients with docu-
mented infections who did not receive concomitant heparin.
These data support the rationale of the phase III double-blind
randomized controlled study exploring the potential benefit of
tifacogin in patients with severe CAP admitted to the intensive
care unit.
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